Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: a pilot clinical trial

Table 4 Liver-function tests

Parameters		Range	Day 0	Year 1	Year 2	Year 3	Year 4	Year 5
	Group		(Mean ± SD)
Total protein
	Placebo + Tamoxifen	66-87	76.68 ± 5.04	76.72 ± 5.89	77.56 ± 5.12	77.32 ± 4.55	75.48 ± 5.28	77.08 ± 5.10
	TRF + Tamoxifen	g/L	76.03 ± 4.71	76.31 ± 5.33	76.41 ± 5.07	76.82 ± 4.55	77.08 ± 4.65	76.54 ± 4.82
Albumin
	Placebo + Tamoxifen.	35-50	41.48 ± 3.78	41.72 ± 3.80	40.84 ± 7.14	42.60 ± 4.29	41.48 ± 3.81	41.40 ± 7.46
	TRF + Tamoxifen	g/L	41.28 ± 3.24	41.36 ± 3.69	41.05 ± 3.64	42.00 ± 4.13	41.69 ± 4.46	41.92 ± 4.07
Total bilirubin
	Placebo + Tamoxifen	< 21	7.80 ± 3.81	7.80 ± 4.17	8.40 ± 3.58	9.16 ± 3.98	8.12 ± 3.70	8.72 ± 4.09
	TRF + Tamoxifen	μM	8.00 ± 3.94	7.74 ± 3.70	7.74 ± 3.88	8.15 ± 4.63	7.95 ± 3.72	8.16 ± 3.89
Alkaline phosphatase
	Placebo + Tamoxifen	42-98	65.08 ± 17.09	63.88 ± 15.21	64.56 ± 19.58	66.80 ± 17.14	62.12 ± 15.14	65.28 ± 18.92
	TRF + Tamoxifen	U/L	66.67 ± 18.55	62.51 ± 20.15	66.18 ± 20.41	64.74 ± 18.44	67.79 ± 20.06	68.42 ± 19.92
Alanine transaminase
	Placebo + Tamoxifen	< 32	28.28 ± 22.69	34.04 ± 50.06	23.28 ± 13.87	27.72 ± 25.74	32.28 ± 48.75	24.28 ± 18.16
	TRF + Tamoxifen	U/L	32.18 ± 29.63	32.85 ± 18.93	31.69 ± 20.55	32.13 ± 28.04	29.77 ± 15.25	28.79 ± 15.14

The mean values of the results from the liver-function tests on day 0 and years 1, 2, 3, 4, and 5 of tocotrienol-rich fraction (TRF)-plus-tamoxifen supplemented group and placebo-plus-tamoxifen supplemented group.

ISSN: 1465-542X